Week 48 resistance analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF versus Atazanavir + Ritonavir + Emtricitabine/Tenofovir DF in HIV-1 infected women (WAVES study GS-US-236-0128).
Discussion: But on the other side, a stable rate of selection was also observed for some NRTI mutations (such as Y115F, L210W) and several NNRTI mutations (such as L100I, K101E, P225H and M230L).
Antiretroviral activity and safety of once-daily etravirine in treatment-naive HIV-infected adults: 48-week results.
Result: All 3 participants who had genotype testing showed RAMs; two had isolated RAMs (one E138K and the other Y181C), and the third had multiple RAMs (V75I, E138K, Y181C, M184I, K219E, and M230L).
Sub-Epidemics Explain Localized High Prevalence of Reduced Susceptibility to Rilpivirine in Treatment-Naive HIV-1-Infected Patients: Subtype and Geographic Compartmentalization of Baseline Resistance Mutations.
PMID: 26651266
2016
AIDS research and human retroviruses
Method: Evidence of transmitted HIV-1 drug resistance (TDR) was defined by the presence of at least one surveillance drug resistance mutation (SDRM) from the consensus genotypic definition of Bennett et al., including major RVP-RAMs L100I+K103N, Y181C/I/V, Y188L, and M230L, and minor RPV-RAMs L100I, K103S, V106A, V179F, and G190A/E/S.
Method: Major RPV resistance-associated mutations (RPV-RAMs) were defined based on data from the clinical trials, phenotypic RPV resistance analyses, and package inserts: K101E/P, E138A/G/K/Q/R<
Systematic review to determine the prevalence of transmitted drug resistance mutations to rilpivirine in HIV-infected treatment-naive persons.
Rilpivirine and Doravirine Have Complementary Efficacies Against NNRTI-Resistant HIV-1 Mutants.
PMID: 27124362
2016
Journal of acquired immune deficiency syndromes (1999)
Result: As described above, both compounds were tested against M230L (which should be similar to M230I).
Result: HIV-1 variants G190A, P236L, and L100I/K103N were susceptible to DOR (<2 nM), however the G190S mutant showed a modest reduction in susceptibility (4.6 +- 1.2 nM) while the M230L mutant and the K103N/P225H double mutant had substantial decreases in their respective susceptibilities (51.1 +- 6.5 nM and 25.3 +- 4.5 nM, respectively).
Result: We chose NNRTI resistant mutants that are known to contribute to virological failure in HIV-infected
Treatment failure and drug resistance in HIV-positive patients on tenofovir-based first-line antiretroviral therapy in western Kenya.
PMID: 27231099
2016
Journal of the International AIDS Society
Table: M230L
Usefulness of an HIV DNA resistance genotypic test in patients who are candidates for a switch to the rilpivirine/emtricitabine/tenofovir disoproxil fumarate combination.
PMID: 27231280
2016
The Journal of antimicrobial chemotherapy
Abstract: Rilpivirine/emtricitabine/tenofovir disoproxil fumarate RAMs studied were K65R, L100I, K101E/P, E138A/G/K/R/Q, V179L, Y181C/I/V, M184V/I, Y188L, H221Y, F227C and M230I/L in the RT.
Rilpivirine as a Treatment for HIV-infected Antiretroviral-naive Adolescents: Week 48 Safety, Efficacy, Virology and Pharmacokinetics.
PMID: 27294305
2016
The Pediatric infectious disease journal
Abstract: Eight patients experienced virologic failure, including 5 who developed rilpivirine resistance-associated mutations, mostly E138K, K101E and M230L.
Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitors.
PMID: 25421485
2015
Antimicrobial agents and chemotherapy
Abstract: The amino acid substitutions E138Q/R, Y181I/V, and M230L conferred high-level resistance to ETR, while K101P and Y181I/V conferred high-level resistance to RPV.
HIV mutation literature information.
PMID: 
2017
HIV clinical trials
Browser Board
Co-occurred Entities
Filtrator
ViMRT